Epidemiology and natural history of Wilson’s disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016 by Lai, CL et al.
Title
Epidemiology and natural history of Wilson’s disease in the
Chinese: A territory-based study in Hong Kong between 2000
and 2016
Author(s) Cheung, KS; Seto, WKW; Fung, JYY; Mak, LY; Lai, CL; Yuen,RMF
Citation World Journal of Gastroenterology, 2017, v. 23, p. 7716-7726
Issued Date 2017
URL http://hdl.handle.net/10722/252245
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
World Journal of 
Gastroenterology
World J Gastroenterol  2017 November 21; 23(43): 7653-7812
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)
Published by Baishideng Publishing Group Inc
SEDITORIAL
7653	 Noncoding	RNAs	as	drivers	of	the	phenotypic		plasticity	of	oesophageal	mucosa
Fassan M, Facchin S, Munari G, Fanelli GN, Lorenzon G, Savarino E
MINIREVIEWS
7657	 Functional	interaction	of	endoplasmic	reticulum	stress	and	hepatitis	B	virus	in	the	pathogenesis	of	liver	
diseases
Kim SY, Kyaw YY, Cheong J
7666	 Pathological	process	of	liver	sinusoidal	endothelial	cells	in	liver	diseases
Ni Y, Li JM, Liu MK, Zhang TT, Wang DP, Zhou WH, Hu LZ, Lv WL
ORIGINAL ARTICLE
Basic Study
7678	 Resveratrol	modifies	biliary	secretion	of	cholephilic	compounds	in	sham-operated	and	cholestatic	rats
Dolezelova E, Prasnicka A, Cermanova J, Carazo A, Hyrsova L, Hroch M, Mokry J, Adamcova M, Mrkvicova A, Pavek P, 
Micuda S
7693	 Chitinase	3-like	1	secreted	by	peritumoral	macrophages	in	esophageal	squamous	cell	carcinoma	is	a	
favorable	prognostic	factor	for	survival
Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL
7705	 Palmitate	induces	fat	accumulation	by	activating	C/EBPβ-mediated	G0S2	expression	in	HepG2	cells
Zhao NQ, Li XY, Wang L, Feng ZL, Li XF, Wen YF, Han JX
Retrospective Cohort Study
7716	 Epidemiology	and	natural	history	of	Wilson’s	disease	in	the	Chinese:	A	territory-based	study	in	Hong	Kong	
between	2000	and	2016
Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF
Retrospective Study
7727	 Efficacy	of	thalidomide	therapy	in	pediatric	Crohn’s	disease	with	evidence	of	tuberculosis
Wang L, Hong Y, Wu J, Leung YK, Huang Y
7735	 Combined	endovascular	brachytherapy,	sorafenib,	and	transarterial	chemobolization	therapy	for	
hepatocellular	carcinoma	patients	with	portal	vein	tumor	thrombus
Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP
Contents Weekly  Volume 23  Number 43  November 21, 2017
 November 21, 2017|Volume 23|ssue 43|WJG|www.wjgnet.com
Contents
World Journal of Gastroenterology
Volume 23  Number 43  November 21, 2017
7746	 Procedure-related	complications	in	gastric	variceal	obturation	with	tissue	glue
Guo YE, Miao HB, Wen ZF, Xuan JY, Zhou HX
7756	 Gastric	xanthelasma	and	metabolic	disorders:	A	large	retrospective	study	among	Chinese	population
Chen Y, He XJ, Zhou MJ, Li YM
Clinical Trials Study
7765	 Application	of	superb	microvascular	imaging	in	focal	liver	lesions
He MN, Lv K, Jiang YX, Jiang TA
Observational Study
7776	 Chronic	liver	disease	is	universal	in	children	with	biliary	atresia	living	with	native	liver
Lee WS, Ong SY, Foo HW, Wong SY, Kong CX, Seah RB, Ng RT
Prospective Study
7785	 How	severe	is	moderately	severe	acute	pancreatitis?	Clinical	validation	of	revised	2012	Atlanta	Classification
Ignatavicius P, Gulla A, Cernauskis K, Barauskas G, Dambrauskas Z
META-ANALYSIS
7791	 Laparoscopic	vs 	open	hepatectomy	for	hepatolithiasis:	An	updated	systematic	review	and	meta-analysis
Li H, Zhang J, Cai JY, Li SH, Zhang JB, Wang XM, Chen GH, Yang Y, Wang GS
CASE REPORT
7807	 Fatal	gastrointestinal	histoplasmosis	15	years	after	orthotopic	liver	transplantation
Agrawal N, Jones DEJ, Dyson JK, Hoare T, Melmore SA, Needham S, Thompson NP
 November 21, 2017|Volume 23|ssue 43|WJG|www.wjgnet.com
NAME	OF	JOURNAL	
World Journal of  Gastroenterology
ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)
LAUNCH	DATE
October 1, 1995
FREQUENCY
Weekly
EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Profes-
sor, Surgeon, Department of  Surgery, Universidad 
Autonoma de Madrid; Department of  General Sur-
gery, Fundacion Jimenez Diaz University Hospital, 
Madrid 28040, Spain
Stephen C Strom, PhD, Professor, Department of  
Laboratory Medicine, Division of  Pathology, Karo-
linska Institutet, Stockholm 141-86, Sweden
Andrzej S Tarnawski, MD, PhD, DSc (Med), 
Professor of  Medicine, Chief Gastroenterology, VA 
Long Beach Health Care System, University of  Cali-
fornia, Irvine, CA, 5901 E. Seventh Str., Long Beach, 
CA 90822, United States
EDITORIAL	BOARD	MEMBERS
All editorial board members resources online at http://
www.wjgnet.com/1007-9327/editorialboard.htm
EDITORIAL	OFFICE
Jin-Lei Wang, Director
Ze-Mao Gong, Vice Director
World Journal of  Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
Contents
EDITORS FOR 
THIS ISSUE
Responsible Assistant Editor: Xiang Li                     Responsible Science Editor: Ke Chen
Responsible Electronic Editor: Yan Huang       Proofing Editorial Office Director: Jin-Lei Wang
Proofing Editor-in-Chief: Lian-Sheng Ma
http://www.wjgnet.com
PUBLICATION	DATE
November 21, 2017
COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles pub-
lished by this Open-Access journal are distributed under 
the terms of  the Creative Commons Attribution Non-
commercial License, which permits use, distribution, 
and reproduction in any medium, provided the original 
work is properly cited, the use is non commercial and is 
otherwise in compliance with the license.
SPECIAL	STATEMENT
All articles published in journals owned by the Baishideng 
Publishing Group (BPG) represent the views and opin-
ions of  their authors, and not the views, opinions or 
policies of  the BPG, except where otherwise explicitly 
indicated.
INSTRUCTIONS	TO	AUTHORS
Full instructions are available online at http://www.
wjgnet.com/bpg/gerinfo/204
ONLINE	SUBMISSION
http://www.f6publishing.com
World Journal of Gastroenterology
Volume 23  Number 43  November 21, 2017
Editorial	 board	member	 of	World	 Journal	 of	Gastroenterology ,	 kenshi	
Matsumoto,	MD,	 PhD,	 Associate	 Professor,	Department	 of	Gastroenterology,	
Juntendo	University,	Tokyo	113-8421,	Japan
World Journal of  Gastroenterology (World J Gastroenterol, WJG, print ISSN 1007-9327, online 
ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. WJG was estab-
lished on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. 
The WJG Editorial Board consists of  1375 experts in gastroenterology and hepatology 
from 68 countries.
    The primary task of  WJG is to rapidly publish high-quality original articles, reviews, 
and commentaries in the fields of  gastroenterology, hepatology, gastrointestinal endos-
copy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastroin-
testinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional ther-
apy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal 
pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterol-
ogy, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biol-
ogy, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, 
gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal 
therapeutics. WJG is dedicated to become an influential and prestigious journal in gas-
troenterology and hepatology, to promote the development of  above disciplines, and to 
improve the diagnostic and therapeutic skill and expertise of  clinicians.
World Journal of  Gastroenterology (WJG) is now indexed in Current Contents®/Clinical Medicine, 
Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index 
Medicus, MEDLINE, PubMed, PubMed Central and Directory of  Open Access Journals. The 
2017 edition of  Journal Citation Reports® cites the 2016 impact factor for WJG as 3.365 (5-year 
impact factor: 3.176), ranking WJG as 29th among 79 journals in gastroenterology and hepatol-
ogy (quartile in category Q2). 
I-IX  Editorial	Board
ABOUT COVER
INDEXING/ABSTRACTING
AIMS AND SCOPE
FLYLEAF
 November 21, 2017|Volume 23|ssue 43|WJG|www.wjgnet.com
Ka-Shing Cheung, Lung-Yi Mak, Department of Medicine, The 
University of Hong Kong, Queen Mary Hospital, Hong Kong 
999077, China
Wai-Kay Seto, James Fung, Ching-Lung Lai, Man-Fung 
Yuen, Department of Medicine, The University of Hong Kong, 
Queen Mary Hospital, Hong Kong 999077, China
Wai-Kay Seto, James Fung, Ching-Lung Lai, Man-Fung 
Yuen, State Key Laboratory for Liver Research, The University 
of Hong Kong, Hong Kong 999077, China
ORCID number: Ka-Shing Cheung (0000-0002-4838-378X); 
Wai-Kay Seto (0000-0002-9012-313X); James Fung (0000-0002 
-1286-8902); Lung-Yi Mak (0000-0002-2266-3935); Ching-Lung 
Lai (0000-0002-5927-2436); Man-Fung Yuen (0000-0001-7985 
-7725).
Author contributions: Cheung KS designed and performed 
the study, were involved in statistical analysis and interpretation 
of the data, and wrote the manuscript; Seto WK and Mak LY 
performed the study, statistical analysis and interpretation of 
the data; Fung J, Lai CL and Yuen MF revised and edited the 
manuscript.
Institutional review board statement: This study was 
approved by The Institutional Review Board of The University of 
Hong Kong/Hospital Authority, Hong Kong West Cluster.
Informed consent statement: The Institutional Review Board 
of The University of Hong Kong/Hospital Authority waived the 
need for written informed consent as there were no direct contact 
with eligible subjects and no additional blood taking.
Conflict-of-interest statement: The authors have no conflicts of 
interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Unsolicited manuscript
Correspondence to: Man-Fung Yuen, Professor, Depart-
ment of Medicine, The University of Hong Kong, Queen Mary 
Hospital, Pokfulam Road, Hong Kong 999077, 
China. mfyuen@hkucc.hku.hk
Telephone: +852-22553984
Fax: +852-28162863
Received: July 28, 2017  
Peer-review started: July 30, 2017
First decision: August 29, 2017
Revised: September 25, 2017 
Accepted: September 28, 2017  
Article in press: September 28, 2017
Published online: November 21, 2017
Abstract
AIM
To investigate the epidemiology and natural history of 
Wilson’s disease in the Chinese.
METHODS
Data were retrieved via electronic search of hospital 
medical registry of the Hong Kong Hospital Authority, 
which covers all the public healthcare services. We 
identified cases of Wilson’s disease between 2000 and 
2016 by the International Classification of Diseases 
(ICD)-9 code. We analyzed the incidence rate, pre-
valence and adverse outcomes of Wilson’s disease.
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RESULTS
We identified 211 patients (male cases 104; female 
cases 107; median age 27.2 years, IQR: 17.1-38.6 
years; duration of follow-up 8.0 years, IQR: 5.0-14.0 
years). The average annual incidence rate was 1.44 per 
million person-years while the prevalence was 17.93 per 
million. Between 2000 and 2016, there was a decrease 
in the annual incidence rate from 1.65 to 1.23 per 
million person-years (P  = 0.010), whereas there was an 
increase in the annual prevalence from 7.80 to 25.20 
per million (P  < 0.001). Among the 176 cases with 
hepatic involvement, 38 (21.6%) had cirrhosis, three 
(1.7%) developed hepatocellular carcinoma, 24 (13.6%) 
underwent liver transplantations, and 26 (14.8%) died. 
Seven patients had concomitant chronic viral hepatitis 
B or C. The 5-year and 10-years rates of overall survival 
were 92.6% and 89.5%, and for transplant-free 
survival rates 91.8% and 87.4%, respectively. Cirrhosis 
and possibly chronic viral hepatitis were associated with 
poorer overall survival. 
CONCLUSION
There was a significant increase in the prevalence of 
Wilson’s disease in Hong Kong. The prognosis was 
favorable except for those with cirrhosis or concomitant 
viral hepatitis.
Key words: Hepaticolenticular degeneration; Cirrhosis; 
Hepatocellular carcinoma; Transplantation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: There are few studies on the epidemiology 
and natural history of Wilson’s disease in Asia. The 
present territory-based study was the first to describe 
both the epidemiology and natural history of Wilson’s 
disease over a long period of time (a span of 17 years 
from 2000 to 2016) in the Chinese. There was a signi-
ficant increase in the number of cases of Wilson’s 
disease in Hong Kong. The prognosis was favorable 
except for those with cirrhosis or concomitant viral 
hepatitis.
Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. 
Epidemiology and natural history of Wilson’s disease in the 
Chinese: A territory-based study in Hong Kong between 2000 
and 2016. World J Gastroenterol 2017; 23(43): 7716-7726 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i43/7716.htm  DOI: http://dx.doi.org/10.3748/wjg.v23.
i43.7716
INTRODUCTION
Wilson’s disease is an autosomal recessive disease 
with impairment of hepatic excretion of copper, 
leading to excessive copper accumulation in various 
organs and tissues[1]. There is a wide spectrum of 
clinical manifestations including hepatic, neurological, 
psychiatric and ophthalmological involvements. Never­
theless, some patients may be asymptomatic, and 
mutational analysis may be needed for a definitive 
diagnosis[2]. Untreated patients with hepatic involvement 
carry significant morbidities including cirrhosis and 
hepatocellular carcinoma (HCC)[3­5]. Therapies which 
either chelate the copper (D­penicillamine and trientine) 
or inhibit its absorption (zinc) are proven to be effective 
in controlling the disease[6]. 
There are a few population­based studies on 
the epidemiology of Wilson’s disease in the western 
population, but the majority were performed before 
the 1990s. The incidence rate ranges from 17 to 29 
per million person­years[7­10], while the prevalence is 
reported to be 15­30 cases per million population[1,11,12]. 
Recently, a genetic study of Wilson’s disease concluded 
that prevalence of Wilson’s disease may actually be 
even higher (1 in 72016)[13]. Studies are even more 
scarce in Asia, except for one population­based study 
in Taiwan reporting a low incidence (average annual 
incidence rate of 2.7 per million person­years) and 
prevalence (ranging from 8.4 to 16.0 per million) of 
Wilson’s disease between 2000 and 2005[14]. However, 
the study observation period was short, and prognostic 
risk factors were not determined. 
The long­term outcomes of patients with Wilson’s 
disease are reported in the western population but 
not in the Asians[3,4]. However, these are retrospective 
studies and not population­based. In addition, the 
effect of concomitant chronic viral hepatitis B or C 
infection on the outcomes of patients with Wilson’s 
disease has not been examined. This is an important 
factor since around 248 million and 150 million people 
worldwide have chronic hepatitis B (CHB) and C 
(CHC) infection, respectively[15,16] While metabolic risk 
factors (diabetes mellitus, obesity, hypertension as 
well as metabolic syndrome) predispose CHB and CHC 
patients to an increased risk of fibrosis/cirrhosis as well 
as HCC[17,18], whether it will lead to a poorer prognosis 
in patients with Wilson’s disease remains unknown.   
Therefore, there is an unmet need for an update of 
the epidemiology of Wilson’s disease as well as more 
comprehensive identification of risk factors for adverse 
outcomes in the Asians. This will shed light on the 
better management of affected patients. 
The aims of the present study were to determine 
the epidemiology and the natural history of Wilson’
s disease in the Chinese population in Hong Kong. 
In addition, risk factors for liver transplantation 
requirement and mortality were determined.
MATERIALS AND METHODS
Source of data
We retrieved data from the Clinical Data Analysis and 
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Reporting System (CDARS), an electronic database 
managed by the Hong Kong Hospital Authority, which 
is the sole provider of public healthcare services in 
Hong Kong with about 90% of the healthcare services 
being covered[19,20]. Important clinical information 
are all available in the CDRS, which includes patient 
demographics, death, diagnoses, admissions, clinic 
visits, procedures, laboratory results, medication 
prescription and dispensing history[21]. There has 
been an increasing number of territory­based studies 
performed using this electronic database[22­27], with high 
accuracies of the coding system demonstrated[24,28]. 
All patients were anonymized in the CDARS, with 
a unique reference key assigned to each individual. 
Ethics approval was issued by the Institutional Review 
Board, The University of Hong Kong and West Cluster 
of Hospital Authority, Hong Kong.
Study subjects
The study period commenced from 2000 and ended 
in 2016. Cases of Wilson’s disease from 1999 to 
2016 were recognized from the CDARS by using the 
International Classification of Diseases (ICD)-9 code of 
275.1. 
Demographics (age, sex, nationality, diagnosis date 
and death) were retrieved. In addition, information 
on all diagnoses (including various adverse events 
and comorbidities) of patients were available for data 
retrieval. 
The incidence rate as well as prevalence of Wilsons’s 
disease were calculated. Adverse liver events (cirrhosis, 
hepatic complications, HCC and liver transplantation), 
non­liver outcomes, and mortality were also studied. 
Risk factors (including concomitant chronic viral hepa­
titis and metabolic factors) associated with overall and 
transplant­free survival were determined.  
Cases with cirrhosis were identified by the ICD­9 
code of 571.5 and the presence of portal hypertension, 
splenomegaly or cirrhotic complications. Cirrhotic 
complications were defined with the existence of 
at least one of the following: ascites, spontaneous 
bacterial peritonitis, gastroesophageal varices, he­
patic encephalopathy, or hepatorenal syndrome. 
Chronic viral hepatitis referred to either CHB or CHC 
infection. Metabolic factors included diabetes mellitus, 
hypertension, dyslipidemia, obesity and alcoholism. 
Obesity was diagnosed with a body mass index of 25 
kg/m2 or more in the Asian population[29]. Dyslipidemias 
are defined as disorders of lipoprotein metabolism 
with high levels of triglycerides, low­density or non­
high­density lipoprotein cholesterol, or low level of 
high­density lipoprotein cholesterol. The cutoff value 
depends on the individual patient’s cardiovascular risk 
profile[30]. Smoking status was not usually entered into 
the electronic database system. Table 1 illustrates the 
identification of outcomes and covariates.
Validation of data
Diagnosis coding accuracy of the CDARS data was 
validated by reviewing the eletronic medical records of 
patients from our center, Queen Mary Hospital. Queen 
Mary Hospital is a hospital which provides tertiary 
healthcare services including liver transplantation in 
Hong Kong. 
Statistical analysis 
Statistical analyses were done by R version 3.2.3 
(R Foundation for Statistical Computing) statistical 
software. We expressed continuous variables in terms 
of median with interquartile range (IQR), and used 
Mann­Whitney U­test to assess the difference in 
continuous variables between two groups. We used 
χ 2 test or Fisher’s exact test for comparing categorical 
variables. The incidence rate and prevalence of 
Wilson’s disease between 2000 and 2016 were 
calculated. Poisson regression model was used to 
evaluate the temporal trends of count data. Variables 
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Table 1  International classification of diseases-9 code for 
outcome and covariates
Impaired or abnormal liver function 573.8, 794.8
Hepatitis 573.3, 571.40, 571.41
Chronic liver disease 571.9, 573.9
Acute liver failure 570
Chronic liver failure 571.8
Hepatocellular carcinoma 155.0
Cirrhosis 571.5
Viral hepatitis B carrier V02.61:0
Viral hepatitis C carrier V02.62:0
Sequalae of chronic liver disease 572.8
Esophageal varices 456.0, 456.1
Gastric varices 456.8
Ascites 789.5
Spontaneous bacterial peritonitis 567.2
Portal hypertension 572.3
Splenomegaly/Hypersplenism 789.1, 789.2, 789.4
Hepatic encephalopathy 572.2
Hepatorenal syndrome 572.4
Liver transplantation V42.7
Parkinsonism 332
Tremor 781.0
Dystonic disorder 333.6
Convulsion 780.32
Tics 307.20
Dementia 290
Bipolar affective disorder 296.7
Depression 296.2, 296.3, 311
Anxiety 300.0
Organic affective syndrome 293.83
Psychosis 295, 293.83
Personality disorder 301
Suicide E950
Hemolytic anemia 283.10
Alcoholism 291, 571.0, 571.1, 571.2, 571.3, 303, 
305.0, 980.8, 980.9
Obesity 278.0, 278.1
Diabetes mellitus 249, 250
Hypertension 401-405
Dysplipidemia 272.0-272.4
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(male cases 104; female cases 107). There were 
170 newly diagnosed cases (male, 84; female, 86). 
The median follow­up duration was 8.0 years (IQR 
5.0 to 14.0 years), with a total follow­up of 1559.5 
person­years. Patients were diagnosed with Wilson’s 
disease at a median age of 27.2 years (IQR 17.1 to 38.6 
years). Sixty­five patients (30.8%) were diagnosed 
before the age of 20. Men were diagnosed with Wilson’
s disease at a similar age as women [28.5 years (IQR 
19.0 to 38.8 years) and 25.0 years (IQR 15.9 to 
38.6 years) for men and women, respectively; p = 
0.326]. On presentation, nine patients had end­stage 
cirrhosis and nine had acute liver failure, requiring 
liver transplantation (8.5% of the total cases). One 
hundred and seventy­six patients (83.4%) had liver 
involvement. Of these, 21.6% developed cirrhosis (n 
= 38). Forty­nine patients (23.2%) had neurological 
and/or psychiatric involvement. Thirty patients (14.2%) 
had neurological involvement, with parkinsonism 
being the commonest manifestation (n = 15; 50.0%). 
Twenty­four patients (11.4%) had psychiatric mani­
festation, with depression being most prevalent (n = 9; 
37.5%). Four patients (16.7%) had history of suicide. 
Twenty­one patients (10.0%) had both hepatic and 
neurological or psychiatric involvement. Non­immune 
mediated hemolytic anemia occurred in eight patients 
(3.8%). Seven patients (3.3%) had concomitant 
chronic viral hepatitis (CHB, 5; CHC, 2), and 17 (8.1%) 
had metabolic factors. 
Table 3 shows the different medications used 
in the patients with neurological and/or psychiatric 
involvement, including anti­parkinson agents, anti­
convulsants, benzodiazepines, propranolol, baclofen, 
tetrabenazine, antidepressants, antipsychotics and 
lithium. 
When patients were divided into three age strata 
(< 20, 20 ­ 39.9, ≥ 40 years), HCC and mortality 
were significantly higher in older age groups, while 
there were no significant differences for other hepatic, 
neurological or psychiatric manifestations (Table 4).
Incidence rate and prevalence 
Between 2000 and 2016, the average annual incidence 
associated with adverse events were identified by 
Cox proportional hazards model. The adverse events 
were analysed by Kaplan­Meier method with statistical 
significance determined by log-rank test. A two-tailed 
p value < 0.05 was regarded as statistically significant. 
RESULTS
Patient characteristics
Two hundred and eleven patients with Wilson’s disease 
were identified. Patient demographics are shown in 
Table 2. Male sex accounted for 49.3% of the cases 
Table 2  Clinical characteristics of patients with Wilson’s 
disease in Hong Kong [n  = 211, n  (%)]
Variables Clinical characteristics
Age 27.9 (18.2-39.7)
Male 104 (49.3)
Drug 193 (91.5)
   D-penicillamine1 129 (61.6)
   Trientine2   22 (10.4)
   Zinc   42 (19.9)
Hepatic disease 176 (83.4)
   Cirrhosis   38 (21.6)
   Cirrhotic complications   19 (10.8)
   Ascites   10 (5.7)
   Spontaneous bacterial peritonitis      5 (2.8)
   Esophageal varices   10 (5.7)
   Gastric varices     5 (2.8)
   Hepatic encephalopathy     8 (4.5)
   Hepatocellular carcinoma     3 (1.7)
Neurological disease   30 (14.2)
   Parkinsonism   15 (50.0)
   Tremor     3 (10.0)
   Dystonia     4 (13.3)
   Tics     1 (3.3)
   Dementia     2 (6.7)
   Seizure     7 (23.3)
Psychiatric disease   24 (11.4)
   Depression     9 (37.5)
   Anxiety     2 (8.3)
   Bipolar disorder     4 (16.7)
   Organic affective syndrome     3 (12.5)
   Psychosis     4 (16.7)
   Personality disorder     3 (12.5)
   Suicide     4 (16.7)
Concomitant hepatic and neurological/
psychiatric diseases 
  21 (10.0)
Non-immune hemolytic anemia     8 (3.8)
Viral hepatitis     7 (3.3)
   Chronic hepatitis B infection     5 (71.4)
   Chronic hepatitis C infection     2 (28.6)
Metabolic factors   17 (8.1)
   Diabetes mellitus     3 (17.6)
   Hypertension     7 (41.2)
   Dyslipidemia     4 (23.5)
   Obesity     4 (23.5)
   Alcoholism     4 (23.5)
Liver transplantation   24 (11.3)
Death   26 (12.3)
1Twenty four patients had concomitant zinc therapy during the initial 
treatment phase or maintenance phase; 2Eight patients had concomitant 
zinc therapy during the initial treatment phase or maintenance phase. 
Age was expressed as median (years) with interquartile range. Categorical 
variables were expressed as n (%).
Table 3  The use of different medications in patients with 
neurological and/or psychiatric involvement
Drugs
Anticonvulsants (carbamazepine and valproate)
Antidepressants (citalopram and fluoxetine)
Anti-parkinson agents (levodopa, bromocriptine, amantadine, 
ropinorole and benzhexol)
Antipyschotics (clozapine, olanzapine, quetiapine, perphenazine, 
paliperidone and trifluoperazine)
Baclofen
Benzodiazepines (clonazepam, diazepam and lorazepam)
Lithium
Propranolol
Tetrabenazine
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rate of Wilson’s disease was 1.44 per million person­
years. There was a decrease in the annual incidence 
rate from 1.65 to 1.23 per million person­years (Poisson 
p = 0.010) (Table 5). The average annual prevalence 
was 17.93 per million. The annual prevalence increased 
from 7.80 to 25.20 per million (Poisson p < 0.001).
Wilson’s disease was more commonly diagnosed 
in the younger age groups, with the incidence rate 
peaking in the 15­ to 19­year age group (Table 6). For 
patients aged less than 25 years, the average annual 
incidence rate ranged from 2.02 to 3.06 per million 
person­years. For those aged between 25 and 44 
years, the average annual incidence rate ranged from 
1.71 to 1.97 per million person­years. Patients were 
less likely to have disease onset at 45 years or older 
(age group 45­49: 0.86 per million person­years; age 
group ≥ 50: 0.29 per million person­years).
Adverse events 
Among the 176 patients with hepatic involvement, 38 
had cirrhosis (21.6%). Nineteen patients (10.8%) had 
cirrhotic complications, with the two most common 
being the development of ascites (n = 10; 5.7%) and 
esophageal varices (n = 10; 5.7%). Around 20% of 
the cirrhotic cases were men (21 out of 104), while 
15.9% were women (17 out of 107) (p = 0.416). The 
median age for the diagnosis of cirrhosis was 33.4 
years [IQR 23.9 to 42.8 years; 32.4 years (IQR 23.7 
to 45.5 years) and 34.1 years (IQR 24.4 to 41.4 years) 
in men and women, respectively; p = 0.772].
Three cases were newly diagnosed with HCC 
(1.7% of cases with hepatic involvement), all of which 
developed in men (age at diagnosis ranged from 45.8 
to 56.0 years). The 5­year and 10­year cumulative 
incidences of HCC were 1.3% (95%CI: 0%­3.1%) 
and 2.3% (95%CI: 0%­4.8%), respectively. The 
time from diagnosis of Wilson’s disease to HCC 
development ranged from 1.7 to 8 years. All three 
patients had underlying cirrhosis, and one of them had 
concomitant CHB infection. None of them received 
liver transplantation, and two died at the age of 47.2 
and 56.8 years. 
Liver transplantations were performed in 24 
patients (11.3% of all cases; 13.6% of cases with 
hepatic involvement) ­­ 14 for cirrhosis and 10 for 
acute liver failure. Twelve out of 104 were men (11.1%) 
Table 4  Clinical characteristics of patients with Wilson’s disease according to different age strata [n  = 211, n  (%)]
Age < 20 (n  = 65) Age 20-39.9 (n  = 94) Age ≥ 40 (n  = 52) P  value
Hepatic involvement 58 (89.2) 74 (78.7) 44 (84.6) 0.201
Cirrhosis 7 (10.8) 18 (19.1) 13 (25.0) 0.128
Cirrhotic complications 4 (6.2) 9 (9.6) 6 (11.5) 0.584
Hepatocellular carcinoma 0 0 3 (11.5) 0.014
Neurological involvement 9 (13.8) 16 (17.0) 5 (9.6) 0.469
Psychiatric involvement 6 (9.2) 12 (12.8) 6 (11.5) 0.787
Liver transplantation 11 (16.9) 11 (11.7) 2 (3.8) 0.066
Death 4 (6.2) 9 (9.6) 13 (25.0) 0.005
Significant P values were bolded.
Table 5  Incidence rate and prevalence of Wilson’s disease in Hong Kong
Yr Total population (million) New cases Total cases Incidence rate (per 
million person-years)
Prevalence (per million) Prevalence 
ratio of M/F
M F T M F T M F T M F T M F T
2000 3.28 3.39 6.67   4   7 11 24 28   52 1.22 2.06 1.65 7.32 8.26 7.80 0.89
2001 3.28 3.43 6.71   6   9 15 28 36   64 1.83 2.62 2.24 8.54 10.5 9.54 0.81
2002 3.28 3.56 6.74   3   8 11 31 44   75 0.91 2.25 1.63 9.45 12.36 11.13 0.76
2003 3.26 3.47 6.73 11   7 18 40 51   91 3.37 2.02 2.67 12.27 14.7 13.52 0.83
2004 3.27 3.52 6.78   9   4 13 47 54 101 2.75 1.14 1.92 14.37 15.34 14.90 0.94
2005 3.26 3.55 6.81   4   5   9 51 57 108 1.23 1.41 1.32 15.64 16.06 15.86 0.97
2006 3.27 3.59 6.86   2   3   5 52 60 112 0.61 0.84 0.73 15.90 16.71 16.33 0.95
2007 3.28 3.63 6.92   2   3   5 54 63 117 0.61 0.83 0.72 16.46 17.36 16.91 0.95
2008 3.29 3.67 6.96   2   2   4 54 63 117 0.61 0.54 0.57 16.41 17.17 16.81 0.96
2009 3.28 3.69 6.97   6 10 16 60 72 132 1.83 2.71 2.30 18.29 19.51 18.94 0.94
2010 3.29 3.73 7.02   9   8 17 68 80 148 2.74 2.14 2.42 20.67 21.45 21.08 0.96
2011 3.30 3.77 7.07   8   3 11 75 83 158 2.42 0.80 1.56 22.73 22.02 22.35 1.03
2012 3.33 3.83 7.15   3   2   5 77 85 162 0.90 0.52 0.70 23.12 22.19 22.66 1.04
2013 3.33 3.86 7.19   2   3   5 79 87 166 0.60 0.78 0.70 23.72 22.54 23.09 1.05
2014 3.35 3.90 7.24   2   8 10 82 94 175 0.60 2.05 1.38 24.48 24.10 24.17 1.02
2015 3.37 3.94 7.31   6   0   6 86 93 179 1.78 0.00 0.82 25.52 23.60 24.49 1.08
2016 3.38 3.96 7.34   5   4   9 89 96 185 1.48 1.01 1.23 26.33 24.24 25.20 1.09
M: Male; F: Female; T: Total.
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and 12 out of 107 were women (11.2%). Five liver 
transplantations were newly performed between 
2000 and 2016. The 5­year and 10­year cumulative 
incidences of liver transplantation were 1.5% 
(95%CI: 0%­3.5%) and 4.2% (95%CI: 0%­8.4%), 
respectively. Patients underwent liver transplantation 
at a median age of 24.4 years (IQR 18.4 to 37.4 
years). There were eight liver transplantation cases 
in patients aged less than 20 years, 11 cases in those 
aged between 20 and 39 years, and five cases in those 
aged between 40 and 59 years. 
Twenty­six patients died between 2000 and 2016 
[male cases 16 (15.0%), female cases 10 (9.6%); p 
= 0.182]. The median time from diagnosis to death 
for these 26 patients was 4.2 years (IQR 2.1 to 5.0 
years). For those newly diagnosed patients receiving 
long­term treatment (n = 154), the 5­year and 
10­year rates of overall survival were 92.6% (95%CI: 
88.3%­97.1%) and 89.5% (95%CI: 84.1%­95.2%), 
respectively (Figure 1A). By univariate analysis, older 
age at diagnosis, cirrhosis, HCC , concomitant chronic 
viral hepatitis and metabolic factors were significant 
risk factors. By multivariate analysis, cirrhosis 
(HR 21.75; 95% CI 5.62 to 84.18) was the only 
independent risk factor, while concomitant chronic viral 
hepatitis was of borderline significance (HR 7.04; 95% 
CI 0.94 to 52.81)(Table 7). 
Figure 2A illustrates the comparison of overall 
survival of patients according to their baseline 
cirrhosis. Patients without cirrhosis had a significantly 
higher rate of overall survival (log­rank p < 0.001), 
with the 5­year and 10­year rates of overall survival 
being 96.5% (95%CI: 93.2%­99.9%) and 95.3% 
(95%CI: 91.4%­99.5%), respectively. For patients 
with cirrhosis, the 5­year and 10­year rates of overall 
survival were 66.9% (95%CI: 48.3%­92.7%) and 
51.0% (95%CI: 30.9%­84.1%), respectively. Figure 
2B illustrates the comparison of overall survival of 
patients according to the presence of chronic viral 
hepatitis. Patients without chronic viral hepatitis had a 
significantly higher rate of overall survival (log-rank p 
= 0.021), with the 5­year and 10­year rates of overall 
survival being 93.1% (95%CI: 88.9%­97.6%) and 
90.9% (95%CI: 85.8%­96.3%), respectively. For 
patients with chronic viral hepatitis, the 5­year and 
10­year rates of overall survival were 80.0% (95%CI: 
51.6%­100%) and 60.0% (95%CI: 29.3%­100%), 
respectively.
The 5­year and 10­year rates of transplant­free 
survival were 91.8% (95%CI: 87.3%­96.6%) and 
87.4% (95%CI: 81.5%­93.8%), respectively (Figure 
1B). By univariate analysis, older age at diagnosis, 
cirrhosis, HCC, concomitant chronic viral hepatitis and 
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Figure 1  Kaplan-Meier survival plot. A: Overall survival; B: Transplant-free survival.
Table 6  Average age-specific incidence rate of Wilson’s 
disease in Hong Kong between 2000 and 2016 
Case number Incidence rate (per million person-years)
Age group M F T M F T
0-4   6   7 13 2.81 3.38 2.61
5-9   3   7 10 1.35 2.73 2.02
10-14   4   9 13 1.30 2.94 2.09
15-19 10 12 22 2.70 3.43 3.06
20-24 10 10 20 2.64 2.52 2.58
25-29   9   6 15 2.33 1.21 1.71
30-34 11   8 19 2.72 1.45 1.97
35-39   9 10 19 1.92 1.70 1.80
40-44 10   9 19 1.92 1.54 1.74
45-49   4   5   9 0.81 0.92 0.86
≥ 50   7   4 11 0.36 0.21 0.29
M: Male; F: Female; T: Total.
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metabolic factors were significant risk factors. By 
multivariate analysis, cirrhosis (HR = 32.16; 95%CI: 
8.58­120.52) and concomitant chronic viral hepatitis 
(HR = 9.97; 95%CI: 1.36­73.05) were independent 
risk factors (Table 7). 
Figure 3A illustrates the transplant­free survival 
of patients with and without baseline cirrhosis. Pati­
ents without cirrhosis had a significantly higher rate 
of transplant­free survival (log­rank p < 0.001), 
with the 5­year and 10­year rates of transplant­free 
survival being 96.5% (95%CI: 93.2%­99.9%) and 
95.3% (95%CI: 91.4%­99.5%), respectively. For 
patients with cirrhosis, the 5­year and 10­year rates 
of transplant­free survival were 61.2% (95%CI: 
42.3%­88.7%) and 33.5% (95%CI: 14.9%­75.2%), 
respectively. Figure 3B illustrates the transplant­free 
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Figure 2  Kaplan-Meier survival plot for overall survival stratified according to baseline cirrhosis status(A) and presence of chronic viral hepatitis (B).
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Figure 3  Kaplan-Meier survival plot for transplant-free survival stratified according to baseline cirrhosis status (A) and presence of chronic viral hepatitis (B).
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survival of patients with and without chronic viral 
hepatitis. Patients without chronic viral hepatitis had 
a significantly higher rate of transplant­free survival 
(log­rank p = 0.032), with the 5­year and 10­year 
rates of transplant­free survival being 92.3% (95%CI: 
87.9%­97.0%) and 88.8% (95%CI: 83.1%­94.9%), 
respectively. For patients with chronic viral hepatitis, 
the 5­ and 10­year rates of transplant­free survival 
were 80.0% (95%CI: 51.6%­100%) and 60.0% 
(95%CI: 29.3%­100%), respectively.
Data validation
Of the 211 patients with Wilson’s disease identified, 80 
patients (37.9%) had follow­up in our hospital. After 
cross validating with the medical records, 77 were 
confirmed to have Wilson’s disease (positive predictive 
value (PPV) of 96.3%). 
Of the 77 patients, we could not ascertain in 10 
patients whether they were index cases or diagnosed 
by family screening. For the remaining 67 cases, 
59 (88.1%) were index cases and 8 (11.9%) were 
diagnosed by family screening. All cases were 
diagnosed of Wilson’s disease in accordance to 
the AALSD or EASL guidelines. Sixty­five patients 
(84.4%) had liver manifestations, while 25 (32.5%) 
had neurological and/or psychiatric manifestations 
[18 (23.4%) and 11 (14.3%) had neurological and 
psychiatric manifestations, respectively].
DISCUSSION
Currently, population­based studies on the epide­
miology as well as the natural history of Wilson’s 
disease are lacking in both the western and Asian 
populations, and the majority of them were done 
before the 1990s. The present territory­based study 
was the first to describe both the epidemiology and 
natural history of Wilson’s disease over a long period 
of time (a span of 17 years from 2000 to 2016) in the 
Chinese. The population­based nature of this study, in 
which the data were retrieved via electronic search of 
hospital medical registry, enables complete capture of 
all cases under the care of our public health system. 
This helps to minimize selection bias inherent in studies 
conducted in tertiary referral centers or selected 
hospitals. Cases were identified by ICD-9 coding, with 
local studies showing high coding accuracies[24,28]. We 
also confirmed a PPV of 96.3% for the coding accuracy 
of Wilson’s disease in the CDARS. 
The incidence rate and prevalence of Wilson’
s disease were estimated to be 17 to 29 per million 
person­years[8,9] and 30 per million, respectively[1,11] 
In comparison, the estimates from our study were 
lower, with an average annual incidence rate of 1.44 
Table 7  HRs and 95%CIs for the association between different covariates and overall survival, transplant-free survival
Univariate analysis Multivariate analysis
HR 95%CI HR 95%CI
Overall survival
Age1 1.04 1.02-1.07 1.03 0.99-1.08
Male sex 1.49 0.52-4.29
Hepatic disease 0.92 0.21-4.13
Cirrhosis 15.42 5.15-46.18 21.75 5.62-84.18
Hepatocellular carcinoma 12.42 2.71-56.93 2.23 0.38-13.32
Chronic viral hepatitis2 4.95 1.09-22.44 7.04 0.94-52.81
Neurological or psychiatric disease 1.11 0.35-3.55
Metabolic factors3 4.37 1.37-13.96 2.68 0.59-12.17
Drug
  Penicillamine Reference -
  Trientine 2.30 0.61-8.63
  Zinc 0.30 0.04-2.39
transplant-free survival
Age1 1.04 1.01-1.07 1.03 0.98-1.07
Male sex 1.45 0.54-3.88
Hepatic disease 1.09 0.25-4.80
Cirrhosis 21.34 7.34-61.99 32.16 8.58-120.52
Hepatocellular carcinoma 11.25 2.48-50.92 1.93 0.34-11.07
Chronic viral hepatitis2 4.48 0.998-20.09 9.97 1.36-73.05
Neurological or psychiatric disease 1.27 0.44-3.66
Metabolic factors3 3.59 1.16-11.16 2.51 0.60-10.54
Drug
  D-penicillamine Reference -
  Trientine 1.97 0.54-7.17
  Zinc 0.26 0.03-1.97
1Age was treated as a continuous variable in the analysis; 2Chronic viral hepatitis was defined as the presence of either chronic hepatitis B or C infection; 
3Metabolic factors were defined as the presence of one of the following: diabetes mellitus, hypertension, dyslipidemia, obesity or alcoholism. Significant risk 
factors were bolded.
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per million person­years, and an average annual 
prevalence of 17.93 per million. These estimates were 
in line with what were reported in Taiwan between 
2000 and 2005 (an average annual incidence rate of 
2.7 per million person­years and a prevalence ranging 
from 8.4 to 16.0 per million). The lower incidence 
rate may be partly due to under diagnosis. However, 
whether Wilson’s disease is genuinely less common 
in Asia requires confirmation from more population­
based studies. 
From the present study, the annual incidence rate 
of Wilson’s disease in Hong Kong had been decreasing, 
from 1.65 to 1.23 per million person­years between 
2000 and 2016. This is likely attributed to the ageing 
population. As shown in Table 4, the incidence rate 
of Wilson’s disease peaked in the 15­ to 19­year age 
group (3.06 per million person­years), while it was 
extremely low among individuals aged 45 or more. 
Between 2000 and 2016, population aged less than 
20 has decreased from 1.59 million to 1.17 million, 
while the population aged 50 or more has increased 
from 1.63 million to 2.92 million in Hong Kong[31]. On 
the other hand, the prevalence of Wilson’s disease has 
been increasing, from 7.80 to 24.49 per million. This is 
likely related to the availability of effective treatment. 
It has been shown that treatment is associated with 
hepatic and neurological improvements in 82%­90% 
and 55%­69% of patients, respectively[4,6].
In the current study, the median age at diagnosis 
was 27.2 years, with the highest incidence rate 
observed in the 15­ to 19­year age group. The 
proportions of cases in different age strata in our 
study [age < 20: 58 cases (30.8%); age 20­39: 
73 cases (44.5%); age ≥ 40: 39 cases (24.6%)] 
were consistent with that reported by the Taiwanese 
population­based study [age < 20: 115 cases (37.5%); 
age 20­39: 127 cases (41.4%); age ≥ 40: 65 cases 
(21.2%)][14]. Men and women were equally affected as 
shown in our study and also previous studies[3,4,14,32]. 
The proportion of patients with neurological and/or 
psychiatric involvement was relatively low in our study 
(n = 49, 23.2%), although some studies also reported 
a similar rate of 24%­27%[3,33]. As for our center, 25 
out of 77 patients (32.5%) had neurological and/or 
psychiatric involvement. This slightly higher proportion 
of neurological/psychiatric involvement is likely to 
be explained by the fact that our center is a tertiary 
referral hospital and is the only center which provides 
liver transplantation services in our locality.   
However, a significant proportion of patients 
with hepatic involvement still had liver­related 
complications, with 21.6% having cirrhosis, 10.8% 
having cirrhotic complications, 1.7% developing HCC, 
and 13.6% undergoing liver transplantations. Around 
12% of the total cases died during the observation 
period, with the 5­year and 10­year rates of overall 
survival being 92.6% and 89.5%, respectively. 
Factors that could modify the transplant­free 
survival included the presence of cirrhosis (HR = 
32.16) and concomitant chronic viral hepatitis (HR 
= 9.97). This highlights the importance of early 
diagnosis and treatment in reducing the copper load 
in the body to prevent development of cirrhosis. 
Future prospective studies with larger sample size 
are required to ascertain whether early treatment 
to suppress hepatitis B virus replication and to cure 
hepatitis C virus infection will be useful in improving 
the prognosis of patients with concomitant chronic viral 
hepatitis. The presence of metabolic factors was shown 
to be associated with lower transplant­free survival 
by univariate but not multivariate analysis. There are 
two possible reasons. First, as metabolic factors are 
associated with increasing age and cirrhosis[17,18,34], the 
potential risk of metabolic factors per se as shown by 
univariate analysis was attenuated after adjusting for 
the effect of age and cirrhosis in multivariate analysis. 
Second, the present study may be underpowered to 
detect this potential effect due to the relatively small 
sample size.    
There are some limitations of the current study. 
First, a small proportion of healthcare services (around 
10%) is not covered by the Hospital Authority[19], 
and hence some patients attending private hospitals 
will not be captured in the CDARS. As such, the 
incidence rate and prevalence of Wilson’s disease 
might be underestimated. Nevertheless, the majority 
of these patients are likely to be captured in the 
CDARS eventually, because of preference for long­
term follow­up in the public hospitals or having con­
sultation for other illnesses in our locality. Second, 
information regarding biochemical response to various 
treatment (D­penicillamine, trientine and zinc) could 
not be retrieved. Third, whether Wilson’s disease was 
diagnosed in accordance to the international guidelines 
(AALSD or EASL guidelines) could not be confirmed 
in other centers. However, this limitation was unlikely 
to have significant impact as it is the standard 
practice that all patients with suspected Wilson’s 
disease in Hong Kong are referred to hepatologists. 
As an example, all 77 cases who followed up in our 
center were diagnosed according to the international 
guidelines. Fourth, we could not ascertain whether 
these patients were index cases or were detected 
by family screening. As for our center, only 8 cases 
(11.9%) were diagnosed by family screening. In 
addition, diagnosis of Wilson’s disease in patients 
with neurological symptoms is usually delayed for a 
longer time from onset than in patients with hepatic 
symptoms[35]. The incidence rate of Wilson’s disease 
in our cohort should therefore be interpreted in this 
context. Lastly, some of the medications used to treat 
the neurological and/or psychiatric symptoms (e.g., 
anticonvulsants) could potentially lead to deranged 
liver function, which may be wrongly regarded as 
liver involvement due to Wilson’s disease by simply 
referring to the ICD coding.
These limitations may be addressed by colla­
boration between all public and private hospitals in the 
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future. In this way, an even more precise estimate of 
the epidemiology of Wilson’s disease could be derived, 
and other potential risk factors for reduced transplant­
free survival (e.g., metabolic factors) could be further 
investigated. 
In conclusion, the epidemiology of Wilson’s disease 
was described in a well defined Chinese population, with 
identification of risk factors for overall and transplant-
free survival. There was a significant increase in the 
prevalence of Wilson’s disease in Hong Kong. Early 
diagnosis and treatment as well as control of concom­
itant chronic viral hepatitis to improve prognosis could 
potentially reduce the disease complications. 
ARTICLE HIGHLIGHTS
Research background
There are few studies on the epidemiology and natural history of Wilson’s 
disease in the Chinese population. The authors conducted a territory-based 
study in Hong Kong (HK) with a population of 7.3 million to address this issue.
Research motivation
Epidemiology data are important for recognizing the temporal trend of a 
particular disease, understanding the natural history and risk factors, as well as 
for resource allocation. 
Research objectives
To investigate the epidemiology and natural history of Wilson’s disease in the 
Chinese population.
Research methods
Data were retrieved from the Clinical Data Analysis and Reporting System 
(CDARS) and Clinical Management System (CMS) of the Hong Kong Hospital 
Authority. The study observation period was from 2000 to 2016. Cases of 
Wilson’s disease between 1999 and 2016 were identified from CDARS by the 
International Classification of Diseases (ICD)-9 code of 275.1. The incidence 
rate and prevalence of Wilson’s disease between 2000 and 2016 were 
calculated. Evaluation of the count data and temporal trends was assessed by 
Poisson regression model. Cox proportional hazards model was used to identify 
variables that were associated with adverse outcomes. Kaplan-Meier method 
was used to analyze the adverse outcomes.
Research results
The authors identified 211 patients (male-to-female ratio 0.97:1; median age 
27.2 years, IQR: 17.1-38.6 years; median follow-up 8.0 years, IQR: 5.0-14.0 
years). The average annual incidence rate and prevalence were 1.44 per 
million person-years and 17.93 per million, respectively. Between 2000 and 
2016, the annual incidence rate decreased from 1.65 to 1.23 per million person-
years (Poisson p = 0.010), while the annual prevalence increased from 7.80 
to 25.20 per million (Poisson p < 0.001). Among the 176 patients with hepatic 
involvement, 38 (21.6%) had cirrhosis, three (1.7%) developed hepatocellular 
carcinoma, 24 (13.6%) underwent liver transplantations, and 26 (14.8%) died. 
Seven patients had concomitant chronic viral hepatitis B or C. The 5- and 
10-year overall survival rates were 92.6% and 89.5%, and for transplant-free 
survival rates 91.8% and 87.4%, respectively. Cirrhosis and possibly chronic 
viral hepatitis were associated with poorer overall survival.
Research conclusions
There was a considerable increase in the prevalence of Wilson’s disease in the 
Chinese population. The long-term survival was good except in patients with 
cirrhosis or concomitant viral hepatitis.
Research perspectives
The epidemiology of Wilson’s disease was described in a well defined Chinese 
population, and factors associated with overall survival and transplant-free 
survival were identified. Future collaboration with the hepatology units from 
all public and private hospitals is warranted to allow for an even more precise 
estimate of the epidemiology of Wilson’s disease and to investigate other 
potential risk factors for reduced transplant-free survival (e.g., metabolic factors).
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